RecruitingPhase 2NCT06605430

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic and Colorectal Cancer (CanPan-C)

Sponsor

HealthPartners Institute

Enrollment

64 participants

Start Date

Sep 16, 2024

Study Type

INTERVENTIONAL

Conditions

Colorectal Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer Non-resectable

Summary

Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with advanced pancreatic and colorectal cancer, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with advanced pancreatic cancer and colorectal cancer to further study how cannabis can impact their symptom burden.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether medical cannabis can help manage symptoms like nausea, vomiting, loss of appetite, weight loss, and pain in people with advanced pancreatic or colorectal cancer who are undergoing chemotherapy. The goal is to improve quality of life alongside standard cancer treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced (locally advanced or metastatic) pancreatic or colorectal cancer (not neuroendocrine tumors) - Surgery with curative intent is not planned in the next 3 months - You have experienced nausea, vomiting, loss of appetite, weight loss, or pain at least once in the past 14 days - You are starting or recently started standard chemotherapy **You may NOT be eligible if...** - You have a neuroendocrine tumor - You are pregnant or plan to become pregnant - You have contraindications to cannabis use Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMedical Cannabis

The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.

Locations(1)

HealthPartners Cancer Research Center

Saint Louis Park, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06605430

Related Trials

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

NCT056110341 location

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT075621523 locations

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

NCT065898301 location

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

NCT075499581 location

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT0692259118 locations